This is a classic toxic convertible financing that will likely result in massive dilution as Pacific Pier converts at floating discounts and sells shares into the market. Traders should expect persistent selling pressure and further price erosion. Monitor OTLC for additional financings or an uplisting attempt to mitigate the overhang, but near-term outlook remains highly negative.
Price Chart
Executive Summary
Oncotelic Therapeutics entered into a securities purchase agreement with Pacific Pier Capital II, issuing a $178,410 convertible promissory note (net proceeds ~$150,000 after fees and OID) plus 500,000 commitment shares. The note carries 12% interest, a 12% OID, matures in 12 months, and is convertible at the lower of $0.06 fixed or 85% of the lowest VWAP in the prior 10 trading days — a deeply dilutive variable-rate structure typical of distressed financing. The company also granted extensive piggyback registration rights, a 100% participation right in future placements, and covenants restricting other variable-rate transactions. This financing signals acute near-term cash needs and creates significant future dilution risk for existing common shareholders.
Key Financial Metrics
Key Facts
- Oncotelic issued a $178,410 convertible promissory note to Pacific Pier Capital II with a 12% original issue discount and 12% annual interest, netting approximately $150,000 in proceeds after legal fee withholdings.
- The note is convertible at the lower of $0.06 per share or 85% of the lowest trading price in the prior 10 days — a deeply dilutive floating-rate mechanism.
- The company also issued 500,000 commitment shares as additional consideration, representing ~0.11% of the then-outstanding 443.6 million common shares.
- The note includes a 150% default acceleration penalty and a 110% prepayment premium during the first six months.
- Pacific Pier granted a 100% participation right in future securities offerings for 12 months, effectively blocking traditional equity raises and embedding a coercive future-financing dynamic.
- The note contains stringent restrictive covenants prohibiting variable-rate transactions, related-party debt repayments, and asset sales without holder consent.
Financial Impact
Net proceeds of ~$150,000 from a $178,410 note; potential dilution from full conversion could exceed 3 billion shares at current market prices (assuming ~$0.0005 stock price), versus 443.6 million shares outstanding as of June 23, 2026.
Risk Factors
- Extreme dilution risk: the floating conversion price at 85% of the lowest 10-day VWAP could result in hundreds of millions to billions of new shares, overwhelming the thinly traded OTC stock.
- Covenant restrictions: the 100% participation right and ban on variable-rate transactions could force the company into even more unfavorable terms with Pacific Pier if additional capital is needed.
- Default acceleration: the 150% penalty and broad event-of-default triggers (including failure to uplist to NASDAQ within 6 months) create a debt trap that could become immediately due.
- Regulatory/delisting risk: the note requires listing on a national exchange by 6 months post-issuance — failure triggers an event of default and further financial strain.
- Going-concern uncertainty: the financial statements were prepared on a going-concern basis, and this financing suggests acute near-term liquidity pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-031124 |
| Exhibit: ex10-2.htm | 0001493152-26-031124 |
| Document: form8-k.htm | 0001493152-26-031124 |
| Document: 0001493152-26-031124-index-headers.html | 0001493152-26-031124 |
| Document: 0001493152-26-031124-index.html | 0001493152-26-031124 |
| Document: 0001493152-26-031124.txt | 0001493152-26-031124 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.0200 | awaiting T+60 | — | $0.0200 (−0.00%) |
Oct 13, 2026 13d ago | 8-K | $0.0200 | awaiting T+60 | — | $0.0200 (−0.00%) |
Jul 14, 2026 14w ago | 8-K | $0.0400 $0.0200 | ▼ −50.00% | ▼ −52.79% | $0.0200 (−50.00%) |
Jun 29, 2026 17w ago | 8-K | $0.0400 $0.0245 | ▲ +38.75% | ▲ +42.59% | $0.0200 (+50.00%) |
May 5, 2026 24w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −2.06% | $0.0200 (−50.00%) |
Apr 16, 2026 27w ago | 8-K | $0.0400 $0.0360 | ▼ −10.00% | ▼ −17.05% | $0.0200 (−50.00%) |
Apr 2, 2026 29w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −14.16% | $0.0200 (−50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers